Related Experiment Video

Updated: Aug 29, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Treating acute bronchiolitis associated with RSV

Robert William Prasaad Steiner1

  • 1Department of Family and Community Medicine, University of Louisville School of Medicine, Louisville, Kentucky 40202, USA. r.steiner@louisville.edu

American Family Physician
|February 10, 2004
PubMed

Insights

Supportive care is key for infant bronchiolitis from respiratory syncytial virus (RSV). While some treatments show limited effectiveness, infection control measures can reduce hospital-acquired RSV infections.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Pulmonology

Background:

  • Bronchiolosis is a common viral respiratory infection in infants, primarily caused by respiratory syncytial virus (RSV).
  • Current management focuses on supportive care, but the efficacy of various pharmacological interventions remains under investigation.
  • Identifying high-risk infants is crucial for determining appropriate levels of care and potential hospitalization.

Purpose of the Study:

  • To review current treatment strategies for infants with respiratory syncytial virus (RSV) bronchiolitis.
  • To evaluate the effectiveness of different therapeutic interventions, including bronchodilators, corticosteroids, and prophylactic agents.
  • To highlight the importance of infection control in preventing nosocomial RSV transmission.

Main Methods:

  • Literature review of studies on RSV bronchiolitis treatment.
  • Analysis of clinical trial data and meta-analyses regarding treatment efficacy.
  • Examination of guidelines and recommendations from health organizations.

Main Results:

  • Supportive care, including oxygen, suctioning, and hydration, forms the cornerstone of treatment.
  • Inhaled bronchodilators and nebulized epinephrine have not demonstrated consistent efficacy, though some sources suggest possible effectiveness.
  • Corticosteroid use is controversial due to inconsistent meta-analysis results.
  • Prophylaxis with palivizumab can reduce hospitalizations in high-risk infants but faces challenges in administration and cost.
  • Infection-control measures are effective in reducing RSV transmission in healthcare settings.

Conclusions:

  • Supportive care remains the primary treatment for RSV bronchiolitis.
  • The efficacy of bronchodilators, epinephrine, and corticosteroids is not definitively established and warrants further research.
  • Prophylactic options exist for high-risk infants but are limited by practical and economic factors.
  • Implementing infection-control strategies is vital for preventing the spread of RSV in clinical environments.

More Related Videos

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...